Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Targeted therapies in newly diagnosed AML: BCL2, FLT3 and IDH inhibitors

Catherine Lai • 5 Jun 2023
ASCO 2023
Acute Myeloid Leukemia Leukemia Azacitidine Ivosidenib

Catherine Lai, MD, MPH, University of Pennsylvania, Philadelphia, PA, reflects on targeted therapies in the management of newly-diagnosed acute myeloid leukemia (AML), including BCL2, FLT3, and IDH inhibitors, as well as combination approaches, mutation agnostic factors, and toxicities. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Catherine Lai

2:09
Advances in targeted approaches for AML: magrolimab & pivekimab sunirine
Catherine Lai • 5 Jun 2023

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:04
Increasing awareness of germline predispositions to hematological malignancies in pediatric patients
Anupama Rao • 29 Apr 2024
0:57
The development of a UK AML registry
Priyanka Mehta • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals